View Report Details Global Atopic Dermatitis Market Report ----------------------------------------2016
View Report Details Executive Summary The atopic dermatitis market is set to form a prominent segment of the pharmaceutical industry. Atopic dermatitis (AD) is a chronic, inflammatory skin disease of unknown origin that usually starts in early infancy, but also affects a substantial number of adults. Atopic dermatitis is a long lasting skin disease that affects a large percentage of the world's population and is a special type of hypersensitivity that is associated with asthma, inhalant allergies (hay fever), and a chronic dermatitis. The symptoms of atopic dermatitis are itching, red to brownish grey patches and small raised bumps. The main cause of atopic dermatitis is unknown but it is assumed to be caused due to genetics, dry skin and environmental conditions. Multiple factors can trigger or worsen atopic dermatitis, including low humidity, seasonal allergies, exposure to harsh soaps and detergents, and cold weather. There has been no specified biologic till now for atopic dermatitis. But recent efforts by many companies have shown positive results and the first biologic named as dupilumab may get launched in 2017. After that many other products are still in pipeline. The key factors which are anticipated to drive atopic dermatitis market include increase in global population, improvement in the global health care expenditure, accelerated economic growth, pollution and climatic factors and role of triggers. Some of the significant developments of this industry include introduction of new biologics, biomarker in atopic dermatitis and opportunity for new entrants. However, the challenge to be faced ahead is time to be taken in drug adoption, high price and legal regulations. This report offers a comprehensive analysis of the atopic dermatitis market. Furthermore, market dynamics such as key trends and development; and challenges are analyzed in depth. On the contention front, the global stent market is reined by few major players namely Sanofi, Glaxo Smithkline (GSK), AstraZeneca and Roche Holding. The competitive landscape of the respective market, along with the company profiles of the leading players are also discussed in detail.
Increase in global population, rising healthcare expenditure, pollution & climatic factors, and role of triggers will drive the global atopic dermatitis market.
US$ Million
Global Atopic Dermatitis Treatment Forecast by Value (2017E-2025E)
The global atopic dermatitis market is expected to become active by 2017 with US….. million and is estimated to reach US$..... million by 2025.
As of 2015, there are ….. million adults affected with atopic dermatitis globally which is expected to increase gradually and reach ….. million by 2025.
The number of adults diagnosed with atopic dermatitis globally is estimated to increase from …. million in 2015 to ….. million by 2025. There are ….. thousands of adult patients in the US that are refractory to topical therapies and this number is estimated to increase to ……. thousands by 2025.
2017E
2018E
2019E
2020E
2021E
2022E
2023E
2024E
2025E
Global Adult Diagnosed with Atopic Dermatitis by Volume (2015-2025E)
Million
Million
Global Adult Affected with Atopic Dermatitis by Volume (2015-2025E)
2015 2016E 2017E 2018E 2019E 2020E 2021E 2022E 2023E 2024E 2025E 2015 2016E 2017E 2018E 2019E 2020E 2021E 2022E 2023E 2024E 2025E
Introduction of new biologics and the use of biomarkers in atopic dermatitis market are the latest developments and trends. Global Adult with Moderate to Severe Atopic Dermatitis (2015-2025E)
Thousands
The total number of adults suffering from moderate to severe atopic dermatitis is ….. thousands in 2015 and is estimated to increase to …… thousands by 2025. There are ….. thousands of adult patients globally that are refractory to topical therapies and this number is estimated to increase to …. thousands by 2025. The revenue for atopic dermatitis market is estimated to increase from US$..... million in 2017 to US$.... million by 2025 in the US. Over ….. million adults in the European Union are affected with atopic dermatitis as of 2015. The number is expected to increase consistently to US$..... million by 2025.
The US Atopic Dermatitis Treatment Forecast by Value (2017E-2025E) US$ Million
Thousands
Global Adult Refractory to Topical Therapies (2011-2017 E)
2017E 2018E 2019E 2020E 2021E 2022E 2023E 2024E 2025E
Time taken to adopt the drugs, high price and legal regulations are the main challenges to the atopic dermatitis market. The US Adult Affected with Atopic Dermatitis (2015-2025E) There are a total of …. million adults affected with atopic dermatitis in the US and the number is expected to reach ….. million by 2025. Million
It is estimated that ….. thousand patients would be treated in the US by 2017 and the number of treated patients is projected to reach ….. thousand by 2025.
It is estimated that ….. thousand patients would be treated in the European Union by 2018 and the number of treated patients is projected to reach …… thousand by 2025.
The number of adults diagnosed with atopic dermatitis in European Union is estimated to increase from ….. million in 2015 to ……. million by 2025.
The US Treated Patients by Volume (2017E-2025E)
Thousands
Thousands
European Union Treated Patients by Volume (2018E-2025E)
2017E
2018E
2019E
2020E
2021E
2022E
2023E
2024E
2025E
2018E
2019E
2020E
2021E
2022E
2023E
2024E
2025E
Contact Us: View Report Details These are abridged and sanitized sample pages from the comprehensive report on the “ Global Atopic Dermatitis Market � . To know more about this report or for any customized research requirement, please contact the following:
Koncept Analytics
Vikas Gupta BD Manager
CS-36, Second Floor, Ansal Plaza Vaishali, Ghaziabad, U.P. – 201010 T. +91-120-4130959 C: +91-9811715635 vikas@konceptanalytics.com
www.konceptanalytics.com